We are live on ! Find out more
SLNO

Soleno Therapeutics

Delisted

SLNO was delisted on the 15th of May, 2026.

54 hedge funds and large institutions have $599M invested in Soleno Therapeutics in 2023 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,646% more capital invested

Capital invested by funds: $21.8M → $599M (+$577M)

620% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 5

140.82% more ownership

Funds ownership: 62.4%203.22% (+141%)

135% more funds holding

Funds holding: 2354 (+31)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
54
Holders Change
+31
Holders Change %
+134.78%
% of All Funds
0.86%
Holding in Top 10
8
Holding in Top 10 Change
+8
Holding in Top 10 Change %
% of All Funds
0.13%
New
36
Increased
6
Reduced
8
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
51
Citigroup
New York
$3.04K +$623 +103 New
Osaic Holdings
52
Osaic Holdings
Arizona
$2.1K -$4.84K -800 -92%
Group One Trading
53
Group One Trading
Illinois
$1.09K
Wells Fargo
54
Wells Fargo
California
$974 -$42 -7 -18%
ACM
55
AIGH Capital Management
Maryland
-$1.56M -364,306 Closed
BC
56
Birchview Capital
Vermont
-$1.05M -245,127 Closed
WVP
57
Worth Venture Partners
New Jersey
-$390K -90,858 Closed
UBS Group
58
UBS Group
Switzerland
-$64 -15 Closed
Northwestern Mutual Wealth Management
59
Northwestern Mutual Wealth Management
Wisconsin
-$4 -1 Closed

SLNO Hedge Fund Activity: Q3 2023 in Review

54 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2023, worth a combined $599M — up 2,646% from $21.8M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new SLNO positions and 5 closed out — a net gain of 31 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $19.4M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.56M sold.

  • 54 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2023, up from 23 in Q2 2023.
  • Funds reported $599M of Soleno Therapeutics stock for Q3 2023, up 2,646% quarter-over-quarter.
  • 36 funds opened new Soleno Therapeutics positions in Q3 2023 and 5 closed out, a net change of +31 holders.
  • The largest Soleno Therapeutics buyer in Q3 2023 was Vivo Capital, an estimated $19.4M added.
  • The largest Soleno Therapeutics seller in Q3 2023 was AIGH Capital Management, an estimated $1.56M sold.

Based on aggregated 13F filings for Q3 2023.